Literature DB >> 31291647

VprBP mitigates TGF-β and Activin signaling by promoting Smurf1-mediated type I receptor degradation.

Yihao Li1, Chao Cui1, Feng Xie2, Szymon Kiełbasa3, Hailiang Mei4, Maarten van Dinther1, Hans van Dam1, Andreas Bauer5, Long Zhang1,2, Peter Ten Dijke1,2.   

Abstract

The transforming growth factor-β (TGF-β) family controls embryogenesis, stem cell differentiation, and tissue homeostasis. However, how post-translation modifications contribute to fine-tuning of TGF-β family signaling responses is not well understood. Inhibitory (I)-Smads can antagonize TGF-β/Smad signaling by recruiting Smurf E3 ubiquitin ligases to target the active TGF-β receptor for proteasomal degradation. A proteomic interaction screen identified Vpr binding protein (VprBP) as novel binding partner of Smad7. Mis-expression studies revealed that VprBP negatively controls Smad2 phosphorylation, Smad2-Smad4 interaction, as well as TGF-β target gene expression. VprBP was found to promote Smad7-Smurf1-TβRI complex formation and induce proteasomal degradation of TGF-β type I receptor (TβRI). Moreover, VprBP appears to stabilize Smurf1 by suppressing Smurf1 poly-ubiquitination. In multiple adult and mouse embryonic stem cells, depletion of VprBP promotes TGF-β or Activin-induced responses. In the mouse embryo VprBP expression negatively correlates with mesoderm marker expression, and VprBP attenuated mesoderm induction during zebrafish embryogenesis. Our findings thereby uncover a novel regulatory mechanism by which Smurf1 controls the TGF-β and Activin cascade and identify VprBP as a critical determinant of embryonic mesoderm induction.
© The Author(s) (2019). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, IBCB, SIBS, CAS.

Entities:  

Keywords:  Activin; Smurf1; TGF-β type I receptor; mesoderm induction; ubiquitination

Mesh:

Substances:

Year:  2020        PMID: 31291647      PMCID: PMC7109606          DOI: 10.1093/jmcb/mjz057

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  47 in total

1.  A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1.

Authors:  Jianping Jin; Emily E Arias; Jing Chen; J Wade Harper; Johannes C Walter
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

2.  SCFFBXL¹⁵ regulates BMP signalling by directing the degradation of HECT-type ubiquitin ligase Smurf1.

Authors:  Yu Cui; Shan He; Cencan Xing; Kefeng Lu; Jian Wang; Guichun Xing; Anming Meng; Shunji Jia; Fuchu He; Lingqiang Zhang
Journal:  EMBO J       Date:  2011-05-13       Impact factor: 11.598

Review 3.  Specificity and versatility in tgf-beta signaling through Smads.

Authors:  Xin-Hua Feng; Rik Derynck
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

4.  Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.

Authors:  A Nakao; M Afrakhte; A Morén; T Nakayama; J L Christian; R Heuchel; S Itoh; M Kawabata; N E Heldin; C H Heldin; P ten Dijke
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

5.  Fine-tuning BMP7 signalling in adipogenesis by UBE2O/E2-230K-mediated monoubiquitination of SMAD6.

Authors:  Xiaofei Zhang; Juan Zhang; Andreas Bauer; Long Zhang; Douglas W Selinger; Chris X Lu; Peter Ten Dijke
Journal:  EMBO J       Date:  2013-03-01       Impact factor: 11.598

6.  The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.

Authors:  Martine Deckers; Maarten van Dinther; Jeroen Buijs; Ivo Que; Clemens Löwik; Gabri van der Pluijm; Peter ten Dijke
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

7.  VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription.

Authors:  Kyunghwan Kim; Jin-Man Kim; Joong-Sun Kim; Jongkyu Choi; Yong Suk Lee; Nouri Neamati; Jin Sook Song; Kyu Heo; Woojin An
Journal:  Mol Cell       Date:  2013-10-17       Impact factor: 17.970

8.  Targeting WW domains linker of HECT-type ubiquitin ligase Smurf1 for activation by CKIP-1.

Authors:  Kefeng Lu; Xiushan Yin; Tujun Weng; Shenli Xi; Li Li; Guichun Xing; Xuan Cheng; Xiao Yang; Lingqiang Zhang; Fuchu He
Journal:  Nat Cell Biol       Date:  2008-07-20       Impact factor: 28.824

9.  Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activity-dependent self-degradation.

Authors:  Yang Xie; Monika Avello; Markus Schirle; Elizabeth McWhinnie; Yan Feng; Eva Bric-Furlong; Christopher Wilson; Robin Nathans; Jing Zhang; Marc W Kirschner; Shih-Min A Huang; Feng Cong
Journal:  J Biol Chem       Date:  2012-11-26       Impact factor: 5.157

10.  Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFβ signalling and EMT.

Authors:  S M Soond; A Chantry
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

View more
  3 in total

1.  A novel negative regulatory mechanism of Smurf2 in BMP/Smad signaling in bone.

Authors:  Junichi Kushioka; Takashi Kaito; Rintaro Okada; Hiroyuki Ishiguro; Zeynep Bal; Joe Kodama; Ryota Chijimatsu; Melanie Pye; Masahiro Narimatsu; Jeffrey L Wrana; Yasumichi Inoue; Hiroko Ninomiya; Shin Yamamoto; Takashi Saitou; Hideki Yoshikawa; Takeshi Imamura
Journal:  Bone Res       Date:  2020-11-23       Impact factor: 13.567

Review 2.  Posttranslational Modifications of Smurfs: Emerging Regulation in Cancer.

Authors:  Longtao Yang; Wenwen Zhou; Hui Lin
Journal:  Front Oncol       Date:  2021-02-22       Impact factor: 6.244

3.  Smad7 Deficiency in Myeloid Cells Does Not Affect Liver Injury, Inflammation or Fibrosis after Chronic CCl4 Exposure in Mice.

Authors:  Ludmilla Unrau; Jessica Endig; Diane Goltz; Paulina Sprezyna; Hanna Ulrich; Julia Hagenstein; Bernd Geers; Karina Kaftan; Lukas Carl Heukamp; Gisa Tiegs; Linda Diehl
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.